Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Dystrophin-related protein 2 (DRP2) is a cytoskeletal-associated protein most closely related to dystrophin and utrophin, encoded by a gene on chromosome Xq22. DRP2 is expressed principally in the human brain and spinal cord and plays a role in maintaining membrane-associated protein complexes at sites of intercellular contact, particularly within the nervous system[3][4][7]. DRP2 is required for normal myelination and organization of the cytoplasm as well as Cajal band formation in myelinating Schwann cells[4]. Its structure resembles certain short isoforms of dystrophin; it is implicated in proper localization of proteins at the Schwann cell plasma membrane and in possible membrane-cytoskeleton interactions in the central nervous system[4]. Disorders associated with DRP2 dysfunction include spinal muscular atrophy type I and mitochondrial complex IV deficiency (nuclear type 1)[4]. Unlike classical drug targets, DRP2 is not known to function as a receptor, enzyme, transporter, or channel, and there are currently no drugs directly targeting DRP2 nor established use as a clinical biomarker or therapeutic target.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Dystrophin-related protein 2 (DRP2).